Abstract:Background: IgA nephropathy, a frequent cause of end-stage renal disease, is an autoimmune disease wherein immune complexes consisting of IgA1 with galactose-deficient O-glycans (autoantigen) and anti-glycan autoantibodies deposit in glomeruli and induce renal injury. Multiple genetic loci associated with disease risk have been identified. The prevalence of risk alleles varies geographically, highest in eastern Asia and northern Europe, fewer in other parts of Europe and North America, and the least in Africa. IgA nephropathy is diagnosed from pathological assessment of a renal biopsy specimen. Currently, therapy is not disease-targeted but rather is focused on maintaining control of blood pressure and proteinuria, ideally with suppression of angiotensin II. Possible additional approaches differ between countries. Disease-specific therapy as well as new tools for diagnosis, prognosis, and assessment of responses to therapy are needed. Summary: Glycosylation pathways associated with aberrant O-glycosylation of IgA1 and, thus, production of autoantigen, have been identified. Furthermore, unique characteristics of the autoantibodies in IgA nephropathy have been uncovered. Many of these biochemical features are shared by patients with IgA nephropathy and Henoch-Schönlein purpura nephritis, suggesting that the two diseases may represent opposite ends of a spectrum of a disease process. Understanding the molecular mechanisms involved in formation of pathogenic IgA1-containing immune complexes will enable development of disease-specific therapies as well as diagnostic and prognostic biomarkers. Key messages: IgA nephropathy is an autoimmune disease caused by glomerular deposition of nephritogenic circulating immune complexes consisting of galactose-deficient IgA1 (autoantigen) bound by anti-glycan autoantibodies. A better understanding of the multi-step process of pathogenesis of IgA nephropathy and the genetic and environmental contributing factors will lead to development of biomarkers to identify patients with progressive disease who would benefit from a future disease-specific therapy.

Title Page Immunoproteasome in IgA Nephropathy: State-of-Art and Future Perspectives

Progress in Pathogenesis of Immunoglobin A Nephropathy

Immunoproteasome In Iga Nephropathy: State-Of-Art And Future Perspectives

Integrated Proteomics and Metabolomics to Study IgA Nephropathy on Early Stage and Identification of Biomarkers

IgA Nephropathy: Current Understanding and Perspectives on Pathogenesis and Targeted Treatment

Podocyte‐related Proteins in Membranous Nephropathy Progression

The pathogenesis of IgA nephropathy and implications for treatment

Proteins induced by telomere dysfunction are associated with human IgA nephropathy.

[Immunoglobulin A (IgA) and its cellular receptors: Recent advances and new pathogenetical hypothesis]

Current understanding and new insights in the treatment of IgA nephropathy

New Insights into the Pathogenesis of IgA Nephropathy

Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China.

Glomerular diseases: emerging tests and therapies for IgA nephropathy

Single-Cell Transcriptomics Reveal Immune Mechanisms of the Onset and Progression of IgA Nephropathy.

Comprehensive Analyses of the Immunoglobulin Proteome for the Classification of Glomerular Diseases

Immunoglobulin A nephropathy: a pathophysiology view

State-of-Art Therapeutics in IgA Nephropathy

Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies

Treatment of IgA Nephropathy: A Rapidly Evolving Field

Familial aggregation of chronic respiratory disease: use of National Health Interview Survey data for specific hypothesis testing.

IgA Nephropathy: Emerging Mechanisms of Disease